By Angela McDaniels
Seattle, Oct. 28 - The Molecular Profiling Institute, Inc. said it has secured $7.5 million in capital through a series B financing from AmeriPath, Affymetrix and Gen-Probe Inc.
The funding will be used to launch molecular tests and to develop assays through clinical trials.
"Our series B funding will accelerate the introduction of our new genetic-based profiling to oncology patients," said Robert J. Penny, Molecular Profiling president and chief executive officer.
Molecular Profiling is reference laboratory in Phoenix that provides testing facilities, prognostic testing services and resources for genomic and proteomic profiling and treatment of cancers.
| Issuer: | Molecular Profiling Institute Inc.
|
| Issue: | Series B financing
|
| Amount: | $7.5 million
|
| Investors: | AmeriPath, Affymetrix and Gen-Probe Inc.
|
| Announcement Date: | Oct. 28
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
